TK216 for relapsed/refractory Ewing sarcoma: Interim phase 1/2 results.

Joseph A. Ludwig,Noah C. Federman,Peter M. Anderson,Margaret E. Macy,Richard F. Riedel,Lara E. Davis,Najat C. Daw,Jade Wulff,AeRang Kim,Ravin Ratan,Edwina Baskin-Bey,Jeffrey A. Toretsky,James Bradley Breitmeyer,Paul A. Meyers

TK216 for relapsed/refractory Ewing sarcoma: Interim phase 1/2 results.

2021

Joseph A. Ludwig
Noah C. Federman
Peter M. Anderson
Margaret E. Macy
Richard F. Riedel
Lara E. Davis
Najat C. Daw
Jade Wulff
AeRang Kim
Ravin Ratan
Edwina Baskin-Bey
Jeffrey A. Toretsky
James Bradley Breitmeyer
Paul A. Meyers

11500Background: Ewing Sarcoma (ES) is a rare cancer of the young with very few treatment options in the relapsed/refractory (R/R) setting. Fusions of the EWS gene and one of five different ETS tra...

Keywords:

Medicine
Internal medicine
treatment options
rare cancer
Interim
Sarcoma
Oncology
Refractory
relapsed refractory

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations